nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefadroxil—Hepatic failure—Docetaxel—pancreatic cancer	0.00384	0.00384	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Gemcitabine—pancreatic cancer	0.00372	0.00372	CcSEcCtD
Cefadroxil—Arthralgia—Tamoxifen—pancreatic cancer	0.00363	0.00363	CcSEcCtD
Cefadroxil—Arthralgia—Erlotinib—pancreatic cancer	0.00359	0.00359	CcSEcCtD
Cefadroxil—Muscle spasms—Sunitinib—pancreatic cancer	0.00351	0.00351	CcSEcCtD
Cefadroxil—Agranulocytosis—Gemcitabine—pancreatic cancer	0.0035	0.0035	CcSEcCtD
Cefadroxil—Haemoglobin—Irinotecan—pancreatic cancer	0.00347	0.00347	CcSEcCtD
Cefadroxil—Haemorrhage—Irinotecan—pancreatic cancer	0.00345	0.00345	CcSEcCtD
Cefadroxil—Agranulocytosis—Fluorouracil—pancreatic cancer	0.00344	0.00344	CcSEcCtD
Cefadroxil—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.00341	0.00341	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Epirubicin—pancreatic cancer	0.00339	0.00339	CcSEcCtD
Cefadroxil—Haemoglobin—Gemcitabine—pancreatic cancer	0.00338	0.00338	CcSEcCtD
Cefadroxil—Thrombocytopenia—Erlotinib—pancreatic cancer	0.00337	0.00337	CcSEcCtD
Cefadroxil—Creatinine increased—Epirubicin—pancreatic cancer	0.00337	0.00337	CcSEcCtD
Cefadroxil—Haemorrhage—Gemcitabine—pancreatic cancer	0.00337	0.00337	CcSEcCtD
Cefadroxil—Angioedema—Sunitinib—pancreatic cancer	0.00334	0.00334	CcSEcCtD
Cefadroxil—Haemoglobin—Fluorouracil—pancreatic cancer	0.00333	0.00333	CcSEcCtD
Cefadroxil—Haemorrhage—Fluorouracil—pancreatic cancer	0.00331	0.00331	CcSEcCtD
Cefadroxil—Phosphatase alkaline increased—Epirubicin—pancreatic cancer	0.00321	0.00321	CcSEcCtD
Cefadroxil—Vaginal inflammation—Epirubicin—pancreatic cancer	0.00321	0.00321	CcSEcCtD
Cefadroxil—Erythema multiforme—Gemcitabine—pancreatic cancer	0.00318	0.00318	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00317	0.00317	CcSEcCtD
Cefadroxil—Convulsion—Sunitinib—pancreatic cancer	0.00316	0.00316	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Doxorubicin—pancreatic cancer	0.00314	0.00314	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00314	0.00314	CcSEcCtD
Cefadroxil—Creatinine increased—Doxorubicin—pancreatic cancer	0.00312	0.00312	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Docetaxel—pancreatic cancer	0.00311	0.00311	CcSEcCtD
Cefadroxil—Cramp muscle—Docetaxel—pancreatic cancer	0.00311	0.00311	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Docetaxel—pancreatic cancer	0.00311	0.00311	CcSEcCtD
Cefadroxil—Arthralgia—Sunitinib—pancreatic cancer	0.00311	0.00311	CcSEcCtD
Cefadroxil—Dyspepsia—Tamoxifen—pancreatic cancer	0.00306	0.00306	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Docetaxel—pancreatic cancer	0.00304	0.00304	CcSEcCtD
Cefadroxil—Dyspepsia—Erlotinib—pancreatic cancer	0.00303	0.00303	CcSEcCtD
Cefadroxil—Blood urea increased—Epirubicin—pancreatic cancer	0.00303	0.00303	CcSEcCtD
Cefadroxil—Vaginal infection—Epirubicin—pancreatic cancer	0.00303	0.00303	CcSEcCtD
Cefadroxil—Aplastic anaemia—Epirubicin—pancreatic cancer	0.00301	0.00301	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.003	0.003	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00297	0.00297	CcSEcCtD
Cefadroxil—Vaginal inflammation—Doxorubicin—pancreatic cancer	0.00297	0.00297	CcSEcCtD
Cefadroxil—Phosphatase alkaline increased—Doxorubicin—pancreatic cancer	0.00297	0.00297	CcSEcCtD
Cefadroxil—Thrombocytopenia—Sunitinib—pancreatic cancer	0.00292	0.00292	CcSEcCtD
Cefadroxil—Muscle spasms—Irinotecan—pancreatic cancer	0.00289	0.00289	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00284	0.00284	CcSEcCtD
Cefadroxil—Pancytopenia—Docetaxel—pancreatic cancer	0.00283	0.00283	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00281	0.00281	CcSEcCtD
Cefadroxil—Blood urea increased—Doxorubicin—pancreatic cancer	0.0028	0.0028	CcSEcCtD
Cefadroxil—Vaginal infection—Doxorubicin—pancreatic cancer	0.0028	0.0028	CcSEcCtD
Cefadroxil—Neutropenia—Docetaxel—pancreatic cancer	0.00279	0.00279	CcSEcCtD
Cefadroxil—Aplastic anaemia—Doxorubicin—pancreatic cancer	0.00279	0.00279	CcSEcCtD
Cefadroxil—Urticaria—Tamoxifen—pancreatic cancer	0.00276	0.00276	CcSEcCtD
Cefadroxil—Abdominal pain—Tamoxifen—pancreatic cancer	0.00275	0.00275	CcSEcCtD
Cefadroxil—Abdominal pain—Erlotinib—pancreatic cancer	0.00272	0.00272	CcSEcCtD
Cefadroxil—Body temperature increased—Erlotinib—pancreatic cancer	0.00272	0.00272	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00271	0.00271	CcSEcCtD
Cefadroxil—Vertigo—Irinotecan—pancreatic cancer	0.0027	0.0027	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Epirubicin—pancreatic cancer	0.00268	0.00268	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.00266	0.00266	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00264	0.00264	CcSEcCtD
Cefadroxil—Dyspepsia—Sunitinib—pancreatic cancer	0.00262	0.00262	CcSEcCtD
Cefadroxil—Hepatic failure—Epirubicin—pancreatic cancer	0.00259	0.00259	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00257	0.00257	CcSEcCtD
Cefadroxil—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00256	0.00256	CcSEcCtD
Cefadroxil—Asthenia—Tamoxifen—pancreatic cancer	0.0025	0.0025	CcSEcCtD
Cefadroxil—Convulsion—Fluorouracil—pancreatic cancer	0.0025	0.0025	CcSEcCtD
Cefadroxil—Arthralgia—Gemcitabine—pancreatic cancer	0.00249	0.00249	CcSEcCtD
Cefadroxil—Agranulocytosis—Docetaxel—pancreatic cancer	0.00248	0.00248	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Doxorubicin—pancreatic cancer	0.00248	0.00248	CcSEcCtD
Cefadroxil—Asthenia—Erlotinib—pancreatic cancer	0.00247	0.00247	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.00247	0.00247	CcSEcCtD
Cefadroxil—Pruritus—Tamoxifen—pancreatic cancer	0.00246	0.00246	CcSEcCtD
Cefadroxil—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00245	0.00245	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00244	0.00244	CcSEcCtD
Cefadroxil—Pruritus—Erlotinib—pancreatic cancer	0.00244	0.00244	CcSEcCtD
Cefadroxil—Thrombocytopenia—Irinotecan—pancreatic cancer	0.0024	0.0024	CcSEcCtD
Cefadroxil—Haemoglobin—Docetaxel—pancreatic cancer	0.0024	0.0024	CcSEcCtD
Cefadroxil—Hepatic failure—Doxorubicin—pancreatic cancer	0.0024	0.0024	CcSEcCtD
Cefadroxil—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00239	0.00239	CcSEcCtD
Cefadroxil—Haemorrhage—Docetaxel—pancreatic cancer	0.00239	0.00239	CcSEcCtD
Cefadroxil—Diarrhoea—Tamoxifen—pancreatic cancer	0.00238	0.00238	CcSEcCtD
Cefadroxil—Abdominal pain—Sunitinib—pancreatic cancer	0.00236	0.00236	CcSEcCtD
Cefadroxil—Body temperature increased—Sunitinib—pancreatic cancer	0.00236	0.00236	CcSEcCtD
Cefadroxil—Diarrhoea—Erlotinib—pancreatic cancer	0.00235	0.00235	CcSEcCtD
Cefadroxil—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00235	0.00235	CcSEcCtD
Cefadroxil—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00234	0.00234	CcSEcCtD
Cefadroxil—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.0023	0.0023	CcSEcCtD
Cefadroxil—Dizziness—Tamoxifen—pancreatic cancer	0.0023	0.0023	CcSEcCtD
Cefadroxil—Dizziness—Erlotinib—pancreatic cancer	0.00228	0.00228	CcSEcCtD
Cefadroxil—Erythema multiforme—Docetaxel—pancreatic cancer	0.00226	0.00226	CcSEcCtD
Cefadroxil—Vomiting—Tamoxifen—pancreatic cancer	0.00221	0.00221	CcSEcCtD
Cefadroxil—Hypersensitivity—Sunitinib—pancreatic cancer	0.0022	0.0022	CcSEcCtD
Cefadroxil—Rash—Tamoxifen—pancreatic cancer	0.00219	0.00219	CcSEcCtD
Cefadroxil—Dermatitis—Tamoxifen—pancreatic cancer	0.00219	0.00219	CcSEcCtD
Cefadroxil—Vomiting—Erlotinib—pancreatic cancer	0.00219	0.00219	CcSEcCtD
Cefadroxil—Somnolence—Irinotecan—pancreatic cancer	0.00218	0.00218	CcSEcCtD
Cefadroxil—Blood creatinine increased—Epirubicin—pancreatic cancer	0.00218	0.00218	CcSEcCtD
Cefadroxil—Headache—Tamoxifen—pancreatic cancer	0.00218	0.00218	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00218	0.00218	CcSEcCtD
Cefadroxil—Rash—Erlotinib—pancreatic cancer	0.00217	0.00217	CcSEcCtD
Cefadroxil—Dermatitis—Erlotinib—pancreatic cancer	0.00217	0.00217	CcSEcCtD
Cefadroxil—Dyspepsia—Irinotecan—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Cefadroxil—Headache—Erlotinib—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00214	0.00214	CcSEcCtD
Cefadroxil—Asthenia—Sunitinib—pancreatic cancer	0.00214	0.00214	CcSEcCtD
Cefadroxil—Somnolence—Gemcitabine—pancreatic cancer	0.00213	0.00213	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00212	0.00212	CcSEcCtD
Cefadroxil—Pruritus—Sunitinib—pancreatic cancer	0.00211	0.00211	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.0021	0.0021	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.0021	0.0021	CcSEcCtD
Cefadroxil—Somnolence—Fluorouracil—pancreatic cancer	0.00209	0.00209	CcSEcCtD
Cefadroxil—Dyspepsia—Fluorouracil—pancreatic cancer	0.00207	0.00207	CcSEcCtD
Cefadroxil—Nausea—Tamoxifen—pancreatic cancer	0.00207	0.00207	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00206	0.00206	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.00205	0.00205	CcSEcCtD
Cefadroxil—Nausea—Erlotinib—pancreatic cancer	0.00204	0.00204	CcSEcCtD
Cefadroxil—Diarrhoea—Sunitinib—pancreatic cancer	0.00204	0.00204	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00203	0.00203	CcSEcCtD
Cefadroxil—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.00202	0.00202	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00201	0.00201	CcSEcCtD
Cefadroxil—Muscle spasms—Docetaxel—pancreatic cancer	0.002	0.002	CcSEcCtD
Cefadroxil—Eosinophilia—Epirubicin—pancreatic cancer	0.00199	0.00199	CcSEcCtD
Cefadroxil—Dizziness—Sunitinib—pancreatic cancer	0.00197	0.00197	CcSEcCtD
Cefadroxil—Abdominal pain—Irinotecan—pancreatic cancer	0.00194	0.00194	CcSEcCtD
Cefadroxil—Body temperature increased—Irinotecan—pancreatic cancer	0.00194	0.00194	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.00194	0.00194	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00194	0.00194	CcSEcCtD
Cefadroxil—Pancytopenia—Epirubicin—pancreatic cancer	0.00191	0.00191	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.0019	0.0019	CcSEcCtD
Cefadroxil—Vomiting—Sunitinib—pancreatic cancer	0.00189	0.00189	CcSEcCtD
Cefadroxil—Body temperature increased—Gemcitabine—pancreatic cancer	0.00189	0.00189	CcSEcCtD
Cefadroxil—Neutropenia—Epirubicin—pancreatic cancer	0.00188	0.00188	CcSEcCtD
Cefadroxil—Rash—Sunitinib—pancreatic cancer	0.00188	0.00188	CcSEcCtD
Cefadroxil—Dermatitis—Sunitinib—pancreatic cancer	0.00188	0.00188	CcSEcCtD
Cefadroxil—Urticaria—Fluorouracil—pancreatic cancer	0.00187	0.00187	CcSEcCtD
Cefadroxil—Headache—Sunitinib—pancreatic cancer	0.00187	0.00187	CcSEcCtD
Cefadroxil—Body temperature increased—Fluorouracil—pancreatic cancer	0.00186	0.00186	CcSEcCtD
Cefadroxil—Eosinophilia—Doxorubicin—pancreatic cancer	0.00184	0.00184	CcSEcCtD
Cefadroxil—Hypersensitivity—Irinotecan—pancreatic cancer	0.00181	0.00181	CcSEcCtD
Cefadroxil—Convulsion—Docetaxel—pancreatic cancer	0.0018	0.0018	CcSEcCtD
Cefadroxil—Drowsiness—Epirubicin—pancreatic cancer	0.00179	0.00179	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.00178	0.00178	CcSEcCtD
Cefadroxil—Arthralgia—Docetaxel—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Cefadroxil—Nausea—Sunitinib—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Cefadroxil—Pancytopenia—Doxorubicin—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Cefadroxil—Asthenia—Irinotecan—pancreatic cancer	0.00176	0.00176	CcSEcCtD
Cefadroxil—Neutropenia—Doxorubicin—pancreatic cancer	0.00174	0.00174	CcSEcCtD
Cefadroxil—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00173	0.00173	CcSEcCtD
Cefadroxil—Asthenia—Gemcitabine—pancreatic cancer	0.00172	0.00172	CcSEcCtD
Cefadroxil—Anaphylactic shock—Docetaxel—pancreatic cancer	0.0017	0.0017	CcSEcCtD
Cefadroxil—Pruritus—Gemcitabine—pancreatic cancer	0.00169	0.00169	CcSEcCtD
Cefadroxil—Diarrhoea—Irinotecan—pancreatic cancer	0.00168	0.00168	CcSEcCtD
Cefadroxil—Agranulocytosis—Epirubicin—pancreatic cancer	0.00167	0.00167	CcSEcCtD
Cefadroxil—Pruritus—Fluorouracil—pancreatic cancer	0.00166	0.00166	CcSEcCtD
Cefadroxil—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00166	0.00166	CcSEcCtD
Cefadroxil—Drowsiness—Doxorubicin—pancreatic cancer	0.00166	0.00166	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.00165	0.00165	CcSEcCtD
Cefadroxil—Diarrhoea—Gemcitabine—pancreatic cancer	0.00164	0.00164	CcSEcCtD
Cefadroxil—Dizziness—Irinotecan—pancreatic cancer	0.00162	0.00162	CcSEcCtD
Cefadroxil—Haemoglobin—Epirubicin—pancreatic cancer	0.00162	0.00162	CcSEcCtD
Cefadroxil—Haemorrhage—Epirubicin—pancreatic cancer	0.00161	0.00161	CcSEcCtD
Cefadroxil—Diarrhoea—Fluorouracil—pancreatic cancer	0.00161	0.00161	CcSEcCtD
Cefadroxil—Vomiting—Irinotecan—pancreatic cancer	0.00156	0.00156	CcSEcCtD
Cefadroxil—Dizziness—Fluorouracil—pancreatic cancer	0.00155	0.00155	CcSEcCtD
Cefadroxil—Agranulocytosis—Doxorubicin—pancreatic cancer	0.00155	0.00155	CcSEcCtD
Cefadroxil—Rash—Irinotecan—pancreatic cancer	0.00155	0.00155	CcSEcCtD
Cefadroxil—Dermatitis—Irinotecan—pancreatic cancer	0.00155	0.00155	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00155	0.00155	CcSEcCtD
Cefadroxil—Headache—Irinotecan—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Cefadroxil—Erythema multiforme—Epirubicin—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Cefadroxil—Vomiting—Gemcitabine—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Cefadroxil—Somnolence—Docetaxel—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Cefadroxil—Rash—Gemcitabine—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Cefadroxil—Dermatitis—Gemcitabine—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Cefadroxil—Haemoglobin—Doxorubicin—pancreatic cancer	0.0015	0.0015	CcSEcCtD
Cefadroxil—Headache—Gemcitabine—pancreatic cancer	0.0015	0.0015	CcSEcCtD
Cefadroxil—Vomiting—Fluorouracil—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Cefadroxil—Dyspepsia—Docetaxel—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Cefadroxil—Haemorrhage—Doxorubicin—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Cefadroxil—Rash—Fluorouracil—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Cefadroxil—Dermatitis—Fluorouracil—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Cefadroxil—Headache—Fluorouracil—pancreatic cancer	0.00147	0.00147	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00146	0.00146	CcSEcCtD
Cefadroxil—Nausea—Irinotecan—pancreatic cancer	0.00146	0.00146	CcSEcCtD
Cefadroxil—Nausea—Gemcitabine—pancreatic cancer	0.00142	0.00142	CcSEcCtD
Cefadroxil—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Cefadroxil—Nausea—Fluorouracil—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00139	0.00139	CcSEcCtD
Cefadroxil—Tension—Epirubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Cefadroxil—Nervousness—Epirubicin—pancreatic cancer	0.00136	0.00136	CcSEcCtD
Cefadroxil—Muscle spasms—Epirubicin—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Cefadroxil—Body temperature increased—Docetaxel—pancreatic cancer	0.00134	0.00134	CcSEcCtD
Cefadroxil—Abdominal pain—Docetaxel—pancreatic cancer	0.00134	0.00134	CcSEcCtD
Cefadroxil—Tension—Doxorubicin—pancreatic cancer	0.00127	0.00127	CcSEcCtD
Cefadroxil—Nervousness—Doxorubicin—pancreatic cancer	0.00126	0.00126	CcSEcCtD
Cefadroxil—Vertigo—Epirubicin—pancreatic cancer	0.00126	0.00126	CcSEcCtD
Cefadroxil—Hypersensitivity—Docetaxel—pancreatic cancer	0.00125	0.00125	CcSEcCtD
Cefadroxil—Muscle spasms—Doxorubicin—pancreatic cancer	0.00125	0.00125	CcSEcCtD
Cefadroxil—Asthenia—Docetaxel—pancreatic cancer	0.00122	0.00122	CcSEcCtD
Cefadroxil—Convulsion—Epirubicin—pancreatic cancer	0.00121	0.00121	CcSEcCtD
Cefadroxil—Pruritus—Docetaxel—pancreatic cancer	0.0012	0.0012	CcSEcCtD
Cefadroxil—Arthralgia—Epirubicin—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Cefadroxil—Vertigo—Doxorubicin—pancreatic cancer	0.00117	0.00117	CcSEcCtD
Cefadroxil—Diarrhoea—Docetaxel—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Cefadroxil—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00114	0.00114	CcSEcCtD
Cefadroxil—Convulsion—Doxorubicin—pancreatic cancer	0.00112	0.00112	CcSEcCtD
Cefadroxil—Dizziness—Docetaxel—pancreatic cancer	0.00112	0.00112	CcSEcCtD
Cefadroxil—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00112	0.00112	CcSEcCtD
Cefadroxil—Arthralgia—Doxorubicin—pancreatic cancer	0.0011	0.0011	CcSEcCtD
Cefadroxil—Vomiting—Docetaxel—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Cefadroxil—Rash—Docetaxel—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Cefadroxil—Dermatitis—Docetaxel—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Cefadroxil—Headache—Docetaxel—pancreatic cancer	0.00106	0.00106	CcSEcCtD
Cefadroxil—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.00106	0.00106	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Cefadroxil—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Cefadroxil—Somnolence—Epirubicin—pancreatic cancer	0.00102	0.00102	CcSEcCtD
Cefadroxil—Nausea—Docetaxel—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Cefadroxil—Dyspepsia—Epirubicin—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000988	0.000988	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000965	0.000965	CcSEcCtD
Cefadroxil—Somnolence—Doxorubicin—pancreatic cancer	0.000941	0.000941	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000936	0.000936	CcSEcCtD
Cefadroxil—Dyspepsia—Doxorubicin—pancreatic cancer	0.000932	0.000932	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000914	0.000914	CcSEcCtD
Cefadroxil—Urticaria—Epirubicin—pancreatic cancer	0.000909	0.000909	CcSEcCtD
Cefadroxil—Body temperature increased—Epirubicin—pancreatic cancer	0.000905	0.000905	CcSEcCtD
Cefadroxil—Abdominal pain—Epirubicin—pancreatic cancer	0.000905	0.000905	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000866	0.000866	CcSEcCtD
Cefadroxil—Hypersensitivity—Epirubicin—pancreatic cancer	0.000843	0.000843	CcSEcCtD
Cefadroxil—Urticaria—Doxorubicin—pancreatic cancer	0.000841	0.000841	CcSEcCtD
Cefadroxil—Abdominal pain—Doxorubicin—pancreatic cancer	0.000837	0.000837	CcSEcCtD
Cefadroxil—Body temperature increased—Doxorubicin—pancreatic cancer	0.000837	0.000837	CcSEcCtD
Cefadroxil—Asthenia—Epirubicin—pancreatic cancer	0.000821	0.000821	CcSEcCtD
Cefadroxil—Pruritus—Epirubicin—pancreatic cancer	0.00081	0.00081	CcSEcCtD
Cefadroxil—Diarrhoea—Epirubicin—pancreatic cancer	0.000783	0.000783	CcSEcCtD
Cefadroxil—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00078	0.00078	CcSEcCtD
Cefadroxil—Asthenia—Doxorubicin—pancreatic cancer	0.00076	0.00076	CcSEcCtD
Cefadroxil—Dizziness—Epirubicin—pancreatic cancer	0.000757	0.000757	CcSEcCtD
Cefadroxil—Pruritus—Doxorubicin—pancreatic cancer	0.000749	0.000749	CcSEcCtD
Cefadroxil—Vomiting—Epirubicin—pancreatic cancer	0.000728	0.000728	CcSEcCtD
Cefadroxil—Diarrhoea—Doxorubicin—pancreatic cancer	0.000724	0.000724	CcSEcCtD
Cefadroxil—Rash—Epirubicin—pancreatic cancer	0.000722	0.000722	CcSEcCtD
Cefadroxil—Dermatitis—Epirubicin—pancreatic cancer	0.000721	0.000721	CcSEcCtD
Cefadroxil—Headache—Epirubicin—pancreatic cancer	0.000717	0.000717	CcSEcCtD
Cefadroxil—Dizziness—Doxorubicin—pancreatic cancer	0.0007	0.0007	CcSEcCtD
Cefadroxil—Nausea—Epirubicin—pancreatic cancer	0.00068	0.00068	CcSEcCtD
Cefadroxil—Vomiting—Doxorubicin—pancreatic cancer	0.000673	0.000673	CcSEcCtD
Cefadroxil—Rash—Doxorubicin—pancreatic cancer	0.000668	0.000668	CcSEcCtD
Cefadroxil—Dermatitis—Doxorubicin—pancreatic cancer	0.000667	0.000667	CcSEcCtD
Cefadroxil—Headache—Doxorubicin—pancreatic cancer	0.000663	0.000663	CcSEcCtD
Cefadroxil—Nausea—Doxorubicin—pancreatic cancer	0.000629	0.000629	CcSEcCtD
